Bristol Myers Squibb Reports Positive Late-Stage Results for Two Treatments

Bristol Myers Squibb said two Phase 3 trials met their primary goals, one for the targeted radiation therapy RYZ101 in advanced neuroendocrine tumors and another for admilparant in idiopathic pulmonary fibrosis. RYZ101 improved progression-free survival, while the lower dose of admilparant slowed lung-function decline but the higher dose did not reach statistical significance. The results add momentum to the company's pipeline as it faces patent expirations on major products, though regulatory and commercial outcomes remain uncertain.

Bristol Myers Squibb said on Oct. 12, 2026, that RYZ101 met the main goal of its ACTION-1 Phase 3 study. The targeted actinium-225 therapy improved time without cancer worsening in patients with somatostatin receptor-positive GEP-NETs after prior lutetium-177 treatment. It was compared with investigator-chosen options such as somatostatin analogues, everolimus, and sunitinib; independent reviewers assessed results, and safety matched earlier findings.

The company also reported that admilparant's lower dose slowed lung-function decline in a Phase 3 idiopathic pulmonary fibrosis trial, while the higher dose missed statistical significance. RYZ101 came from RayzeBio, acquired for about $4.1 billion. The findings bolster Bristol Myers' late-stage pipeline before patent expirations, but approval and sales prospects are still unclear.